COMP <GO>
IRMD vs SIBN // RETURN ON INVESTED CAPITAL (ROIC)
iRadimed Corporation (NASDAQ) VS. SI-BONE Inc. (NASDAQ) • 15-METRIC TALLY: IRMD 7
— SIBN 3
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: IRMD
LAST: $85.74 (+2.16%) • MKT CAP: $1.10B
roic
37.70%
LAST: $22.41 (+2.66%) • MKT CAP: $1.00B
roic
-10.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRMD VS. SIBN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRMD | SIBN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 76.70% | 79.60% | -2.90 | SIBN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 37.70% | -10.30% | +48.00 | IRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.9x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.57% | -0.90% | +2.47 | IRMD | /fcf-yield <GO> |
| Operating Margin | 31.20% | -11.10% | +42.30 | IRMD | /operating-margins <GO> |
| Net Profit Margin | 26.80% | -9.40% | +36.20 | IRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 14.40% | 20.20% | -5.80 | SIBN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.37% | 0.00% | +1.37 | IRMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 8.73 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | IRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.1 | 65.9 | -15.80 | SIBN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 41.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.10B | $1.00B | $92.0M | IRMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRMD REV | SIBN REV | IRMD GROSS % | SIBN GROSS % | IRMD FCF | SIBN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $83.8M | $200.9M | 76.7% | 79.6% | $17.2M | -$9.1M |
| FY 2024 | $73.2M | $167.2M | 76.9% | 79.0% | $17.6M | -$22.9M |
| FY 2023 | $65.6M | $138.9M | — | — | $13.5M | -$18.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRMD // BETA —
SIBN // BETA —